Verhoeff B J, Trip M D, Prins M H, Kastelein J J, Reitsma P H
Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Atherosclerosis. 1998 Nov;141(1):161-6. doi: 10.1016/s0021-9150(98)00156-7.
An increased total plasma homocysteine level is an established risk factor for atherosclerotic vascular disease. The plasma level of homocysteine is influenced by both environmental and genetic factors. An important genetic determinant of plasma homocysteine is a common amino acid dimorphism (Ala222Val) in the methylenetetrahydrofolate reductase (MTHFR) gene. Individuals homozygous for the Val allele have significantly higher homocysteine levels than those with an Ala/Val or Ala/Ala genotype. Moreover, the Val/Val genotype has been claimed to be a strong genetic risk factor for atherosclerosis. The aim of the present study is: (1) to determine the risk associated with the MTHFR dimorphism by comparing the genotype distribution in patients with premature atherosclerosis with that in a group of healthy controls; and (2) to investigate the relationship between the MTHFR genotype and parameters of homocysteine metabolism. The patient group consisted of 257 consecutive referred individuals with angiographically proven premature ( <50 years of age) arterial disease (coronary, and/or peripheral vascular disease). A total of 272 healthy hospital workers without a history of vascular disease were selected as a control group. The MTHFR-genotype was determined by PCR and gel-electrophoresis. A methionine-loading test was performed on 245 patients, and, in addition to homocysteine, levels of folate and vitamin B12 were measured. We found a strong correlation between MTHFR genotype and plasma homocysteine levels both before and after methionine loading. In addition, the MTHFR genotype seems important for the inverse relationship between homocysteine and folate and vitamin B12 levels. Lastly, the MTHFR genotype distribution was not different between patient and control groups. MTHFR genotype is a strong determinant of plasma homocysteine levels. Moreover, the plasma level of folate, which by itself influences homocysteine levels, is also dependent on the MTHFR genotype. In Val/Val genotypes, low levels of both folate and B12 lead to a relatively large increase in homocysteine levels. Nevertheless, the MTHFR genotype does not increase the risk for premature coronary artery disease.
血浆总同型半胱氨酸水平升高是动脉粥样硬化性血管疾病公认的危险因素。同型半胱氨酸的血浆水平受环境和遗传因素的影响。血浆同型半胱氨酸的一个重要遗传决定因素是亚甲基四氢叶酸还原酶(MTHFR)基因中常见的氨基酸二态性(Ala222Val)。纯合Val等位基因的个体比具有Ala/Val或Ala/Ala基因型的个体具有显著更高的同型半胱氨酸水平。此外,Val/Val基因型被认为是动脉粥样硬化的一个强大遗传危险因素。本研究的目的是:(1)通过比较早发性动脉粥样硬化患者与一组健康对照者的基因型分布,确定与MTHFR二态性相关的风险;(2)研究MTHFR基因型与同型半胱氨酸代谢参数之间的关系。患者组由257例连续转诊的经血管造影证实患有早发性(<50岁)动脉疾病(冠状动脉和/或外周血管疾病)的个体组成。总共272名无血管疾病史的健康医院工作人员被选为对照组。通过聚合酶链反应(PCR)和凝胶电泳确定MTHFR基因型。对245例患者进行了甲硫氨酸负荷试验,除了测量同型半胱氨酸外,还测量了叶酸和维生素B12水平。我们发现甲硫氨酸负荷前后MTHFR基因型与血浆同型半胱氨酸水平之间存在很强的相关性。此外,MTHFR基因型似乎对同型半胱氨酸与叶酸和维生素B12水平之间的负相关关系很重要。最后,患者组和对照组之间的MTHFR基因型分布没有差异。MTHFR基因型是血浆同型半胱氨酸水平的一个强大决定因素。此外,本身影响同型半胱氨酸水平的叶酸血浆水平也取决于MTHFR基因型。在Val/Val基因型中,叶酸和维生素B12水平较低会导致同型半胱氨酸水平相对大幅升高。然而,MTHFR基因型不会增加早发性冠状动脉疾病的风险